Latest Pharmaceutical Sector News

Sprintex Limited has landed US$321,000 in new purchase orders from its exclusive Indian distributor Euroteck, following the launch of its advanced GR Series Jet Blowers and a key commissioning at Delhi’s Kondli wastewater plant. This momentum underscores Sprintex’s growing footprint in India’s expanding wastewater treatment market.

Mayne Pharma has won a key legal battle against Cosette Pharmaceuticals, clearing the way for its acquisition scheme to proceed pending final approvals. Shareholders can expect the deal to move forward with payments scheduled soon.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

Cann Group Limited has extended the expiry of its National Australia Bank debt facilities by one year to October 2025, maintaining current terms while exploring long-term refinancing options.

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate for FY25 and fully repaid its short-term funding facility, underscoring its commitment to Australian pharmaceutical innovation.

BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.

BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

Opyl Limited has taken a bold step into digital assets by acquiring approximately 2 Bitcoin and securing a $2 million finance facility backed by these holdings, signaling a strategic pivot towards blockchain integration in healthcare technology.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.